Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy 9 Meters Biopharma stock

Own 9 Meters Biopharma stock in just a few minutes.

9 Meters Biopharma, Inc is a business based in the US. 9 Meters Biopharma shares (INNT) are listed on the NASDAQ and all prices are listed in US Dollars. 9 Meters Biopharma employs 8 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in 9 Meters Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INNT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

9 Meters Biopharma share price

Use our graph to track the performance of INNT stocks over time.

9 Meters Biopharma shares at a glance

Information last updated 2021-01-23.
52-week range$0.44 - $0.87
50-day moving average $0.73
200-day moving average $0.61
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.49

Buy 9 Meters Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy 9 Meters Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

9 Meters Biopharma financials

Gross profit TTM $0
Return on assets TTM -193.21%
Return on equity TTM 0%
Profit margin 0%
Book value $0.14
Market capitalisation $23.1 million

TTM: trailing 12 months

Shorting 9 Meters Biopharma shares

There are currently 2.2 million 9 Meters Biopharma shares held short by investors – that's known as 9 Meters Biopharma's "short interest". This figure is 1.7% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting 9 Meters Biopharma shares can be evaluated.

9 Meters Biopharma's "short interest ratio" (SIR)

9 Meters Biopharma's "short interest ratio" (SIR) is the quantity of 9 Meters Biopharma shares currently shorted divided by the average quantity of 9 Meters Biopharma shares traded daily (recently around 519741.86602871). 9 Meters Biopharma's SIR currently stands at 4.18. In other words for every 100,000 9 Meters Biopharma shares traded daily on the market, roughly 4180 shares are currently held short.

However 9 Meters Biopharma's short interest can also be evaluated against the total number of 9 Meters Biopharma shares, or, against the total number of tradable 9 Meters Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 9 Meters Biopharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 9 Meters Biopharma shares in existence, roughly 30 shares are currently held short) or 0.027% of the tradable shares (for every 100,000 tradable 9 Meters Biopharma shares, roughly 27 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against 9 Meters Biopharma.

Find out more about how you can short 9 Meters Biopharma stock.

9 Meters Biopharma share dividends

We're not expecting 9 Meters Biopharma to pay a dividend over the next 12 months.

Have 9 Meters Biopharma's shares ever split?

9 Meters Biopharma's shares were split on a 1:10 basis on 31 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 9 Meters Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for 9 Meters Biopharma shares which in turn could have impacted 9 Meters Biopharma's share price.

9 Meters Biopharma share price volatility

Over the last 12 months, 9 Meters Biopharma's shares have ranged in value from as little as $0.4404 up to $0.87. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 9 Meters Biopharma's is -0.5435. This would suggest that 9 Meters Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, 9 Meters Biopharma has bucked the trend.

9 Meters Biopharma overview

9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site